United States securities and exchange commission logo





                    June 4, 2020

       Joseph Moscato
       Chief Executive Officer
       NuGenerex Immuno-Oncology, Inc.
       10102 USA Today Way
       Miramar, FL 33025

                                                        Re: NuGenerex
Immuno-Oncology, Inc.
                                                            Registration
Statement on Form 10-12G
                                                            Filed March 12,
2020
                                                            File No. 000-56153

       Dear Mr. Moscato:

              We issued comments on the above captioned filing on April 8,
2020. On May 5, 2020,
       we issued a follow-up letter informing you that those comments remained
outstanding and
       unresolved, and absent a substantive response, we would act consistent
with our obligations
       under the federal securities laws.

                As you have not provided a substantive response, we are
terminating our review and will
       take further steps as we deem appropriate. These steps include releasing
publicly, through the
       agency's EDGAR system, all correspondence, including this letter,
relating to the review of your
       filing, consistent with the staff's decision to publicly release comment
and response letters
       relating to disclosure filings it has reviewed.

              Please contact Ada D. Sarmento at 202-551-3798 or Joe McCann at
202-551-6262 with
       any questions.




                    Sincerely,


                    Division of Corporation Finance

                    Office of Life Sciences
       cc:                                              Jeffrey Wofford, Esq.